<!DOCTYPE html><html><head><meta charSet="utf-8" class="next-head"/><title class="next-head">ALiEM Cards</title><meta name="viewport" content="initial-scale=1.0, width=device-width" class="next-head"/><meta charset="utf-8" class="next-head"/><meta http-equiv="x-ua-compatible" content="ie=edge" class="next-head"/><link rel="apple-touch-icon" sizes="180x180" href="/static/Favicons/apple-touch-icon.png" class="next-head"/><link rel="icon" type="image/png" href="/static/Favicons/favicon-32x32.png" sizes="32x32" class="next-head"/><link rel="icon" type="image/png" href="/static/Favicons/favicon-16x16.png" sizes="16x16" class="next-head"/><link rel="mask-icon" href="/static/Favicons/safari-pinned-tab.svg" color="#00b092" class="next-head"/><link rel="shortcut icon" href="/static/Favicons/favicon.ico" class="next-head"/><link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Open+Sans" class="next-head"/><link rel="preload" href="/_next/static/1~ee3OFOv6kXxZUoU_eCb/pages/card.js" as="script"/><link rel="preload" href="/_next/static/1~ee3OFOv6kXxZUoU_eCb/pages/_app.js" as="script"/><link rel="preload" href="/_next/static/1~ee3OFOv6kXxZUoU_eCb/pages/_error.js" as="script"/><link rel="preload" href="/_next/static/runtime/webpack-89179faa512dd01fbb62.js" as="script"/><link rel="preload" href="/_next/static/chunks/commons.ce4c8f8c27f9b1d9e256.js" as="script"/><link rel="preload" href="/_next/static/chunks/styles.9b76ae77785496d5351a.js" as="script"/><link rel="preload" href="/_next/static/runtime/main-cfdfd101abde4b1d3f2a.js" as="script"/><link rel="stylesheet" href="/_next/static/css/commons.b3e9c004.chunk.css"/><link rel="stylesheet" href="/_next/static/css/styles.0fc85b66.chunk.css"/></head><body><div id="__next"><div data-reactroot=""><div><div class="header" role="banner"><div class="header__logo"><a href="/"><img src="/static/logo.svg"/></a></div><div class="header__nav-button"><button class="hamburger hamburger__squeeze"><span class="hamburger__box"><span class="hamburger__inner"></span></span></button></div><nav class="header__nav header__nav--closed" role="navigation"><ul><li><a href="/cards/">Cards</a></li><li><a href="/categories/">Categories</a></li><li><a href="/about/">About</a></li></ul></nav></div><div class="search"><div class="search__input" role="search"><input type="text" placeholder="Search" aria-label="Search for cards" value=""/></div></div></div><main class="content container" role="main"><article role="article"><h1>IV Fluid Formulations for ICU Patients</h1><div class="card"><div class="card__meta"><div><strong>Author: </strong>Michelle Lin, MD</div><div><strong>Updated:</strong> <!-- -->1/3/2012</div></div><div class="card__content"><h1 id="intravenous-fluid-formulations-and-chloride-restrictive-iv-fluids-for-icu-patients">Intravenous Fluid Formulations and Chloride-Restrictive IV Fluids for ICU Patients</h1>
<table>
<thead>
<tr>
<th>Content per 1 L</th>
<th align="right">Lactated Ringer&#39;s</th>
<th align="right">Normal Saline (0.9%)</th>
<th align="right">Plasma-Lyte 148</th>
<th align="right">D5W</th>
<th align="right">D5 1/2NS</th>
<th align="right">5% albumin</th>
</tr>
</thead>
<tbody><tr>
<td>Na (mEq)</td>
<td align="right">130</td>
<td align="right">154</td>
<td align="right">140</td>
<td align="right">|       77</td>
<td align="right">130-160</td>
<td align="right"></td>
</tr>
<tr>
<td>K (mEq)</td>
<td align="right">4</td>
<td align="right">|               5</td>
<td align="right">|</td>
<td align="right">&lt; 1</td>
<td align="right"></td>
<td align="right"></td>
</tr>
<tr>
<td>Cl (mEq)</td>
<td align="right">109</td>
<td align="right">154</td>
<td align="right">98</td>
<td align="right">|       77</td>
<td align="right">130-160</td>
<td align="right"></td>
</tr>
<tr>
<td>Ca (mEq)</td>
<td align="right">3</td>
<td align="right">|</td>
<td align="right">|</td>
<td align="right"></td>
<td align="right"></td>
<td align="right"></td>
</tr>
<tr>
<td>Mg (mEq)</td>
<td align="right">|</td>
<td align="right">3</td>
<td align="right">|</td>
<td align="right"></td>
<td align="right"></td>
<td align="right"></td>
</tr>
<tr>
<td>Lactate (mEq)</td>
<td align="right">28</td>
<td align="right">|</td>
<td align="right">|</td>
<td align="right"></td>
<td align="right"></td>
<td align="right"></td>
</tr>
<tr>
<td>Acetate (mEq)</td>
<td align="right">|</td>
<td align="right">27</td>
<td align="right">|</td>
<td align="right"></td>
<td align="right"></td>
<td align="right"></td>
</tr>
<tr>
<td>Gluconate (mEq)</td>
<td align="right">|</td>
<td align="right">23</td>
<td align="right">|</td>
<td align="right"></td>
<td align="right"></td>
<td align="right"></td>
</tr>
<tr>
<td>Glucose (mg/dL)</td>
<td align="right">|</td>
<td align="right">| 4545</td>
<td align="right">4545</td>
<td align="right"></td>
<td align="right"></td>
<td align="right"></td>
</tr>
<tr>
<td>Osmolarity (mOsm/L)</td>
<td align="right">273</td>
<td align="right">308</td>
<td align="right">294</td>
<td align="right">252</td>
<td align="right">406</td>
<td align="right">309</td>
</tr>
<tr>
<td>pH</td>
<td align="right">6.5</td>
<td align="right">5.0</td>
<td align="right">5.0</td>
<td align="right">4.0</td>
<td align="right">4.5</td>
<td align="right">6.4-7.4</td>
</tr>
<tr>
<td>Other</td>
<td align="right">|</td>
<td align="right">|</td>
<td align="right">| 50 g/L albumin</td>
<td align="right"></td>
<td align="right"></td>
<td align="right"></td>
</tr>
</tbody></table>
<p><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23073953">Yunos et al JAMA 2012 study:</a></p>
<ul>
<li><strong>Design:</strong> Prospective open, label sequential study of 760 ICU patients (control) and 773 ICU patients (study group) at single hospital in Melbourne, Australia</li>
<li><strong>Control period:</strong> Standard IVF per physician preference</li>
<li><strong>Study period:</strong> Chloride-rich IVF (0.9% saline, 4% succinylated gelatin solution, 4% albumin) became restricted and required specialist approval. Standard fluids allowed were chloride-restrictive fluids (Hartmann solution – similar to Lactated Ringer’s, Plasma-Lyte 148, chloride-poor 20% albumin)</li>
</ul>
<p>|                                                                            |  Control period (Chloride-liberal) | Study period (Chloride-restricted)  |  P value  | Odds ratio for Cl-restrictive  fluid use |
| -------------------------------------------------------------------------- | ---------------------------------: | ----------------------------------: | --------: | ---------------------------------------: |
| Mean serum Cr increased in umol/L                                          |                  22.6 (0.26 mg/dL) |                   14.8 (0.17 mg/dL) |       0.3 |                                          |
| Incidence of injury &amp; failure class for &quot;acute kidney injury&quot; (RIFLE defn) |                                14% |                                8.4% | &lt;0.001 |                                     0.52 |
| Use of renal replacement therapy (RRT)                                     |                                10% |                                6.3% |     0.005 |                                     0.52 |</p>
<p><strong>Bottom line:</strong> </p>
<p>Chloride-rich IV fluids were associated with greater acute kidney injury and need for RRT in ICU patients, compared to chloride-restrictive IV fluids. </p>
<p><strong>NOTE:</strong> There was, however, NO difference in mortality, hospital, ICU length of stay, or RRT after hospital discharge.</p>
<h2 id="references">References</h2>
<ul>
<li>Yunos NM, Bellomo R, Hegarty C, Story D, Ho L, Bailey M. Association between a chloride-liberal vs chloride-restrictive intravenous fluid administration strategy and kidney injury in critically ill adults. JAMA. 2012 Oct 17;308(15):1566-72. [<a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23073953">PubMed</a>]</li>
</ul>
</div></div></article></main><div class="footer" role="contentinfo"><div class="container"><div class="row footer__cc"><div class="footer__cc-image"><a rel="license" href="http://creativecommons.org/licenses/by-nc-nd/3.0/"><img alt="creative-commons" src="/static/by-nc-nd.svg"/></a></div><div class="footer__cc-text">This work is licensed under a<!-- --> <a rel="license" href="http://creativecommons.org/licenses/by-nc-nd/3.0/">Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License</a>.</div></div><div class="row footer__links"><div><a href="/contact/">Contact</a></div><div><a href="/contact/">Get Involved</a></div><div><a href="/about/">About</a></div></div><div class="row row--centered"><div class="container footer__disclaimer">ALiEM Cards content is intended for use by healthcare professionals. Users of this site should exercise their own clinical judgment as to the reliability and accuracy of its information. Non-healthcare-professionals who use this site do so at their own risk. Content on this site should not be construed as medical advice. Users should always confer with medical profoessionals regarding decisions about medications, evaluations and other medical treatments.</div></div></div></div></div></div><script>__NEXT_DATA__ = {"props":{"pageProps":{"card":{"slug":"iv-fluids-for-icu-patients","title":"IV Fluid Formulations for ICU Patients","authors":["Michelle Lin, MD"],"categories":[{"slug":"critical-care","name":"Critical Care"}],"created":"2012/01/03","updated":null,"body":"\n# Intravenous Fluid Formulations and Chloride-Restrictive IV Fluids for ICU Patients\n\n|  Content per 1 L    | Lactated Ringer's |  Normal Saline (0.9%) | Plasma-Lyte 148 |  D5W | D5 1/2NS |     5% albumin |\n| ------------------- | ----------------: | --------------------: | --------------: | ---: | -------: | -------------: |\n| Na (mEq)            |               130 |                   154 |             140 |      |       77 |        130-160 |\n| K (mEq)             |                 4 |                       |               5 |      |          |         \u0026lt; 1 |\n| Cl (mEq)            |               109 |                   154 |              98 |      |       77 |        130-160 |\n| Ca (mEq)            |                 3 |                       |                 |      |          |                |\n| Mg (mEq)            |                   |                       |               3 |      |          |                |\n| Lactate (mEq)       |                28 |                       |                 |      |          |                |\n| Acetate (mEq)       |                   |                       |              27 |      |          |                |\n| Gluconate (mEq)     |                   |                       |              23 |      |          |                |\n| Glucose (mg/dL)     |                   |                       |                 | 4545 |     4545 |                |\n| Osmolarity (mOsm/L) |               273 |                   308 |             294 |  252 |      406 |            309 |\n| pH                  |               6.5 |                   5.0 |             5.0 |  4.0 |      4.5 |        6.4-7.4 |\n| Other               |                   |                       |                 |      |          | 50 g/L albumin |\n\n[Yunos et al JAMA 2012 study:](https://www.ncbi.nlm.nih.gov/pubmed/?term=23073953)\n\n- **Design:** Prospective open, label sequential study of 760 ICU patients (control) and 773 ICU patients (study group) at single hospital in Melbourne, Australia\n- **Control period:** Standard IVF per physician preference\n- **Study period:** Chloride-rich IVF (0.9% saline, 4% succinylated gelatin solution, 4% albumin) became restricted and required specialist approval. Standard fluids allowed were chloride-restrictive fluids (Hartmann solution – similar to Lactated Ringer’s, Plasma-Lyte 148, chloride-poor 20% albumin)\n\n|                                                                            |  Control period (Chloride-liberal) | Study period (Chloride-restricted)  |  P value  | Odds ratio for Cl-restrictive  fluid use |\n| -------------------------------------------------------------------------- | ---------------------------------: | ----------------------------------: | --------: | ---------------------------------------: |\n| Mean serum Cr increased in umol/L                                          |                  22.6 (0.26 mg/dL) |                   14.8 (0.17 mg/dL) |       0.3 |                                          |\n| Incidence of injury \u0026 failure class for \"acute kidney injury\" (RIFLE defn) |                                14% |                                8.4% | \u0026lt;0.001 |                                     0.52 |\n| Use of renal replacement therapy (RRT)                                     |                                10% |                                6.3% |     0.005 |                                     0.52 |\n\n**Bottom line:** \n\nChloride-rich IV fluids were associated with greater acute kidney injury and need for RRT in ICU patients, compared to chloride-restrictive IV fluids. \n\n**NOTE:** There was, however, NO difference in mortality, hospital, ICU length of stay, or RRT after hospital discharge.\n\n## References\n\n- Yunos NM, Bellomo R, Hegarty C, Story D, Ho L, Bailey M. Association between a chloride-liberal vs chloride-restrictive intravenous fluid administration strategy and kidney injury in critically ill adults. JAMA. 2012 Oct 17;308(15):1566-72. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/?term=23073953)]\n"}}},"page":"/card","pathname":"/card","query":{"slug":"iv-fluids-for-icu-patients"},"buildId":"1~ee3OFOv6kXxZUoU_eCb","nextExport":true};__NEXT_LOADED_PAGES__=[];__NEXT_REGISTER_PAGE=function(r,f){__NEXT_LOADED_PAGES__.push([r, f])}</script><script async="" id="__NEXT_PAGE__/card" src="/_next/static/1~ee3OFOv6kXxZUoU_eCb/pages/card.js"></script><script async="" id="__NEXT_PAGE__/_app" src="/_next/static/1~ee3OFOv6kXxZUoU_eCb/pages/_app.js"></script><script async="" id="__NEXT_PAGE__/_error" src="/_next/static/1~ee3OFOv6kXxZUoU_eCb/pages/_error.js"></script><script src="/_next/static/runtime/webpack-89179faa512dd01fbb62.js" async=""></script><script src="/_next/static/chunks/commons.ce4c8f8c27f9b1d9e256.js" async=""></script><script src="/_next/static/chunks/styles.9b76ae77785496d5351a.js" async=""></script><script src="/_next/static/runtime/main-cfdfd101abde4b1d3f2a.js" async=""></script></body></html>